Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo